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Abstract
Melanoma is a very aggressive tumor that does not respond well to standard therapeutic approaches, such as radio- and
chemotherapies. Furthermore, acquiring the ability to metastasize in melanoma and many other tumor types is directly
related to incurable disease. The B1 kinin receptor participates in a variety of cancer-related pathophysiological events, such
as inflammation and angiogenesis. Therefore, we investigated whether this G protein-coupled receptor plays a role in tumor
progression. We used a murine melanoma cell line that expresses the kinin B1 receptor and does not express the kinin B2
receptor to investigate the precise contribution of activation of the B1 receptor in tumor progression and correlated events
using various in vitro and in vivo approaches. Activation of the kinin B1 receptor in the absence of B2 receptor inhibits cell
migration in vitro and decreases tumor formation in vivo. Moreover, tumors formed from cells stimulated with B1-specific
agonist showed several features of decreased aggressiveness, such as smaller size and infiltration of inflammatory cells
within the tumor area, higher levels of pro-inflammatory cytokines implicated in the host anti-tumor immune response,
lower number of cells undergoing mitosis, a poorer vascular network, no signs of invasion of surrounding tissues or
metastasis and increased animal survival. Our findings reveal that activation of the kinin B1 receptor has a host protective
role during murine melanoma tumor progression, suggesting that the B1 receptor could be a new anti-tumor GPCR and
provide new opportunities for therapeutic targeting.
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Introduction
Melanoma is a very aggressive and metastatic tumor that does
not respond well to standard therapeutic approaches, such as
radio- and chemotherapies. Consequently, patients diagnosed at
late stages of the disease often have a very poor prognosis, with
survival averaging approximately 8 months [1]. In fact, the
acquisition of a metastatic phenotype is directly related to
incurable disease in many types of tumors, making tumor
metastasis the main cause of death in cancer patients. To reach
secondary organs, tumor cells must acquire the ability to detach
from the primary site, invade the host stroma and reach lymphatic
or blood vessels. Once in the circulation, tumor cells must still
evade the host immune response, survive in the absence of cell
attachment, and be able to adhere and trans-migrate through the
endothelium to reach the target organs [2]. Although the
mechanisms behind each of these multi-step processes are not
completely elucidated, it is known that many tumor cells can
hijack the physiological function of G-protein-coupled receptors
(GPCR) and take advantage of their multiple functions to
proliferate, promote angiogensis, evade immune response and
invade host tissues to colonize secondary organs [3]. However,
emerging information suggests that host cells deploy counterbal-
ance mechanisms to avoid tumor dissemination. To date, a small
number of metastatic suppressor genes have been described that
significantly reduce metastasis in vitro and in vivo [4–5]. One of
these metastasis suppressor genes is KiSS1, the precursor of the
ligand for the Gaq – protein coupled receptor GPR54 [6], which
was originally shown to inhibit melanoma metastasis [4] and more
recently to inhibit CXCR4-mediated chemotactic response in
breast cancer cells [7] and endometrial cancer metastasis [8].
Kinins are important inflammatory mediators that are involved
in many pathophysiological processes. The kallikrein-kinin system
(KKS) response is initiated via the kallikrein-mediated cleavage of
kininogen into bradykinin (BK) or kallidin (KD). These two
peptides are biologically active; however, they can also act as
substrates of carboxypeptidases, originating desArg9-BK and
desArg10-KD. The kinin mediated response occurs through the
GPCRs known as the B1 and B2 receptors [9,10]. While the B2
receptor is ubiquitously expressed and has a high affinity for BK
and KD, the expression of the B1 receptor is inducible by
activation of CREB, AP1 and NFkB transcriptional factors [11],
and once expressed, this receptor binds preferentially to des-Arg9-
BK and des-Arg10-KD. While the role of kinin receptors in
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tumorigenesis is still poorly understood, it has been shown that
angiotensin-I converting enzyme (ACE) inhibitors – a widely used
family of anti-hypertensive drugs – have anti-tumor properties
[12–13]. This finding has been mainly attributed to decreased
angiotensin-II (AngII) formation, which is an octapeptide that
binds to two different G-coupled receptors known as AT1 and
AT2. AT1 is the receptor responsible for the classical effects of
AngII such as vasoconstriction [14] and has also been shown to
play a role in proliferation, tumorigenesis and metastasis [15–16].
Therefore, most of the anti-tumor properties of ACE inhibitors
have been eventually attributed to a decreased AT1 receptor
activation [17–18]. However, ACE also has kininase II activity,
which means that ACE inhibition not only reduces AngII
formation, but also impairs kinin degradation, which ultimately
leads to an increase in kinin availability [19–20]. The presence of
kinin receptors has been reported in several tumors, and a pro-
tumor role has been attributed to kinin B2 receptor [21–22].
Much less is known about the B1 receptor, although it has been
reported that the B1 receptor is up-regulated in pre-malignant and
malignant prostate lesions [23] and that its expression is associated
with better prognosis in estrogen-negative breast cancer patients
[24]. Conversely, it has also been reported that B1 receptor
activation induces expression of COX2 [25], MMP-2 and MMP-9
[26] and that B1 receptor specific antagonists diminish prolifer-
ation in breast cancer cells [27] and decrease primary tumor
growth in lung and prostate xenografts [28] and Ehrlich tumor
models [29]. However, a common feature among these previous
studies is the expression of the kinin B2 receptor. It has been
reported that the B1 receptor may play a pro-tumoral role via
cross-talk with the B2 receptor [30].
Considering that ACE inhibition eventually increases kinin
availability, that activation of B1 receptor has been reported to
inhibit cell migration in normal cells [31], and the fact that the B1
receptor is also a Gaq protein coupled receptor, similar to the
metastatic suppressor receptor GPR54, we hypothesized that B1
receptor activation, in the absence of B2 receptor activation, could
play a host protective role in tumor progression. In this study, we
show that B1 receptor activation inhibits cell migration in vitro and
decreases tumor growth in vivo. Moreover, tumors generated by
neoplastic cells that have been stimulated with B1 receptor agonist
prior to injection in mice are significantly less aggressive, with a
smaller number of tumor cells undergoing cell division, a reduced
vascular network and complete absence of metastatic lymph
nodes, which ultimately leads to an increase in animal survival.
Materials and Methods
Ethics statement
All the experiments were approved and performed in strict
accordance with the guidelines of the Ethics Committee on
Animal Experimentation from Faculty of Medicine at Ribeira˜o
Preto, University of Sa˜o Paulo, (CETEA; protocol 025-2007).
Mice were bred and housed in a specific pathogen-free facility,
with room temperature controlled at 23uC, in a 12 h light/dark
circle, and received food and water ad libitum. Euthanasia was
conducted by cervical dislocation at study endpoint or earlier if
animals met any early removal criteria (lethargy, hunched posture,
or ruffled coat).
Materials
The B1 receptor specific agonist DABK was purchased from
Sigma. The peptide antagonist desArg9 [Leu8]-BK (DLBK) was
synthesized using the Fmoc solid phase strategy [32], hydrolyzed
[33], analyzed to confirm its amino acid sequence by ionic
exchange chromatography and purified by HPLC. To confirm its
biological activity, we tested the antagonist in a rabbit aorta
contraction assay as described previously [34]. All peptides were
solubilized in sterile water. DNAse, all PCR reagents and the
fluorescent probe for intracellular calcium FLUO-3/AM were
purchased from Sigma. Improm II for reverse transcription was
purchased from Promega. Anti-phospho-ERK, anti-ERK1/2,
horseradish peroxidase-conjugated secondary antibodies and an
ECL kit were all purchased from Santa Cruz Biotechnology. B1
receptor antibody was purchased from Abgent and cell culture
media and supplements were purchased from Gibco. cDNA
coding for B2 receptor, which was used to transfect Tm5 cells was
provided by Dr. Joao B. Pesquero [35]. Immunohistochemistry
reagents, including anti-Ki67, anti-CD31, secondary antibodies,
ABC kit and substrate (3,39-diaminobenzidine) were purchased
from Dako, BD Bioscience, Vector Lab and Sigma, respectively.
Cell culture
The Tm5 melanoma cell line and the non-tumorigenic melan-a
cell line were previously characterized and reported by Dr.
Miriam G. Jasiulionis and were maintained in RPMI 1640 pH 6.9
containing 5% FBS and 10 mg/mL of gentamicin, as previously
described [36]. The melan-a cells received 200 nM of phorbol 12-
myristate 13-acetate (PMA). All experiments using cells were
performed using subconfluent cultures (80–90%), and stimulation
was performed in serum-free media. Cells were treated with
antagonist (DLBK 10 mM) 30 min prior to treatment with the
agonist (DABK 1 mM) unless otherwise noted.
In vivo studies
Tm5 cells were stimulated with vehicle or DABK 1 mM in vitro
in serum free media for 24 h and then injected subcutaneously in
the dorsal superior region of C57/BL6 male mice weighting
approximately 25 g. All used drugs, peptides, and medium were
removed by extensively washing cells with PBS prior to injection.
Each animal received 36105 Tm5 cells in 100 ml of serum free
media. Tumor size and weight were monitored daily.
Gene expression analysis
Gene expression was analyzed by either semi-quantitative
(sqPCR) or quantitative PCR (qPCR). Tumor samples from in
vivo experiments were immediately frozen in liquid nitrogen and
then pulverized before extracting total RNA using Trizol reagent
(Invitrogen). One microgram of total RNA was used for DNAse
treatment and subsequent reverse transcription using the Improm
II protocol. For sqPCR analysis, target genes were amplified using
50 ng of cDNA and Taq platinum DNA polymerase. The
amplification procedure consisted of 26 cycles (cyclophilin B) or
40 cycles (all target genes) (1 min294uC, 1 min255uC and
1 min272uC). Samples were loaded into a 1.5% agarose gel
stained with ethidium bromide (1 mg/mL). For qPCR, 10–50 ng
of cDNA, platinum SYBR green qPCR supermix UDG with Rox
and the ABI Prism 7000 sequence detection system were used. We
quantified transcripts relative to the housekeeping gene cyclophilin
B as described previously [37]. All oligonucleotide primers used in
sq and qPCR analyses are listed in table S1 (GAPDH primers
were used as described in [38]).
Western Blotting
Melanoma cells were serum starved for 24 h and received either
vehicle or 1 mM of the B1 receptor agonist DABK for 0, 10, 30, 60
or 180 minutes for ERK activation assay, or 24 h to address kinin
B1 receptor levels. The cells were later lysed in a lysis buffer
Anti-Tumor Effect of the Kinin B1 Receptor
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consisting of Tris-HCl 10 mM, pH 7.5; NaCl 150 mM; EDTA
1 mM; EGTA 1 mM; SDS 0.1%; Nonidet P-40 1%; 1 mM
PMSF, 10 mg/mL leupeptin, 100 mg/mL aprotinin, 10 mM
benzamidine, 1 mM NaF, 1 mM sodium orthovanadate, and
1 mM DTT. The lysate was swirled for 30 minutes at 5uC and
centrifuged at 120006 g for 15 minutes. The supernatant was
subsequently analyzed for protein content. Samples were loaded
into 12% acrylamide gels and separated by SDS-PAGE. Next, the
proteins were transferred onto a nitrocellulose membrane. The
membranes were blocked with BSA 0.1% and incubated with
either anti-pERK, anti-ERK or anti-B1 receptor antibodies
followed by anti-mouse (pERK) or anti-rabbit (ERK and B1
receptor) secondary horseradish peroxidase-conjugated antibodies.
Immunoblots were visualized using an ECL kit and quantified by
densitometry using the software ImageJ (http://rsb.info.nhi.gov/
ij/).
Calcium mobilization assay
Fifty percent confluent cells were loaded with the fluorescent
probe FLUO3/AM (1 mM for 30 minutes at 37uC) and then kept
in a buffer solution containing NaCl 135 mM, KCl 5 mM,
HEPES 10 mM, MgCl2 1 mM, glucose 2 mM, and CaCl2 2 mM
at pH 7.2. Cells were stimulated with either DABK (1 mM),
DLBK (10 mM) or both at the moment of image. Fluorescence
imaging experiments were performed with a scanning laser
confocal microscope (Leica SP5, Leica, Bensheim, Germany) with
a 63X water immersion objective. The fluo-3 fluorescence dye was
excited at 488 nm using an argon ion laser, and the emitted
fluorescence was measured at 510 nm. Time-course software was
used to capture images of the cells (zyt) in the Live Data Mode
acquisition. All experiments were done at room temperature (23–
25uC).
Wound healing assay
The protocol described previously was used with minor
modifications [39]. Briefly, confluent Tm5 or B16F10 cell cultures
were serum starved for 24 h. In experiments that required
expression of B2 receptor, cells were transfected 24 h prior to
serum starvation using lipofectamine and 1ug of DNA (empty
vector or vector cloned with the cDNA coding for the B2
receptor). Monolayers were wounded in a cross shape with a sterile
10 ml pipette tip, washed twice with PBS to remove detached cells
and stimulated with either vehicle or DABK (1 mM) in serum free
media. The crosses were photographed by phase-contrast micros-
copy immediately after wounding and after 24 h of healing. All
pictures were quantified at least three different points using Image
J software to determine the size of the wound. Values from time
zero were subtracted from the 24 h measurements to obtain the
percentage of closure. In addition, it has been observed that cells
lacking E-cadherin frequently break free from the advancing
‘‘wall’’ of cells and migrate into the wound area as lone cells [40], a
process known as single-cell migration. These cells were quantified
by subtracting the number of lone cells in the wound area before
and after 24 h of healing.
Cell viability assay
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium salt)
was added to a final concentration of 0.5 mg/mL into the culture
media and incubated for 3 h at 37uC. Viable cells are able to
reduce MTT, which creates a violet color. The addition of acid
isopropanol (0.04 M HCl) solubilizes the reduced product, which
can be quantified by measuring the absorbance at 570 nm.
Histopathological analyses
Tumor samples were collected with 1 cm of adjacent tissue to
preserve the tumor micro-environment and fixed in 10% formalin.
Paraffin blocks were prepared, sectioned (4 mm) and stained with
hematoxylin and eosin (H&E). Slides were analyzed using a Leitz
Model Aristoplan microscope (Germany) coupled to a Leica
Model DFC280 color camera (Heerbrugg, Germany). Mitotic
cells, and vessels from the tumor as well as peritumor
macrophages, neutrophils and lymphocytes were quantified at a
magnification of 4006 across 10 random, non-coincident micros-
copy fields.
Immunohistochemistry analyses
Sections from paraffin blocks (4 mm) were dewaxed, endogenous
peroxidase was blocked using 3% H2O2 in ethanol 70% and
antigens were retrieved using 10 mM of citric acid. Next, slides
were blocked in PBS/BSA 2.5% and first antibody against Ki67 or
CD31 were diluted in blocking solution 1:50 and incubated
overnight at 4uC. After washes, slides were incubated with
biotinylated anti-rat (Ki67) or anti-mouse (CD31) secondary
antibodies 30 minutes at room temperature and ABC kit for
another 30 minutes also at room temperature. Color development
was performed using 3,39-diaminobenzidine under microscopic
supervision. Once developed, reaction was topped by distillated
water washes, and slides were counterstained with Hematoxylin,
dehydrated and mounted in permanent mounting media. All slides
were scanned using Aperio CS at 4006 magnification and
quantification was assessed using Aperio algorithms.
Statistical analyses
Statistical significance was evaluated by either Student’s t-test
when only two groups were compared or by one-way analysis of
variance (ANOVA) using the Student-Newman-Keuls post-test for
multiple comparison. Differences between mean values were
considered significant when p,0.05.
Results
The kinin B1 receptor is functionally expressed in Tm5
melanoma cells
To investigate the contribution of the kinin B1 receptor in
tumor progression, we first evaluated the expression of key
components of kallikrein-kinin in normal (melan-a) and tumor
(Tm5) cells. We used RT-sqPCR to assess the expression of the
kinin B1 and B2 receptors. Figure 1A shows that none of the cell
lines express the kinin B2 receptor, while they do express the kinin
B1 receptor. Both melan-a and Tm5 cell lines also express
carboxypeptidase M, one of the main enzymes responsible for the
generation of DABK, the selective B1 receptor agonist. In
addition, we also confirmed the expression of B1 receptor in
Tm5 cells at the protein level by western blotting either at basal
state or after agonist stimulation. As seen in figure 1B–C, kinin B1
receptor is present in Tm5 cells and, although its mRNA is up-
regulated after DABK treatment for 24 h, we observed no changes
in the protein levels after the same time of stimulation. Next, to
evaluate if the B1 receptor was functionally active in the Tm5 cells,
we evaluated the intracellular pathways that are activated
following B1 receptor stimulation with its agonist. We first
examined ERK phosphorylation kinetics, obtaining a typical
activation profile following agonist stimulation (figure 1D). In
addition, we measured intracellular calcium concentration, which
rapidly and transiently increased upon agonist stimulation, as
expected for a Gaq-coupled receptor, which is completely
impaired in the presence of the B1 receptor antagonist
Anti-Tumor Effect of the Kinin B1 Receptor
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Figure 1. The kinin B1 receptor is functionally expressed in Tm5 melanoma cells. (A) Expression levels of the kinin B1 and B2 receptors,
carboxypeptidase M (CPM) and cyclophilin B as a housekeeping gene in melanocytes (melan-a) and melanoma cells (Tm5) evaluated by RT-sqPCR.
cDNA from mice hearts was used as a positive control, and water was used as a negative control. (B–C) Kinin B1 receptor is present at protein level in
Tm5 cells. Agonist stimulation of the cells has no effect in B1 receptor protein level, however a significant increase in mRNA level was detected. The
activity of the B1 receptor in Tm5 cells was accessed by western blotting for ERK phosphorylation (D) and confocal microscopy using FLUO3-AM to
evaluate intracellular calcium mobilization (E) after stimulation with the agonist DABK and blockage by the antagonist DLBK. All results are
representative or quantification of 3–5 independent experiments. Data are expressed as the mean 6 SEM; * p,0.05, with respect to non-stimulated
cells; DABK: desArg9-bradykinin; DLBK: desArg9-[Leu8]-bradykinin.
doi:10.1371/journal.pone.0064453.g001
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(figure 1E). These results indicated that the Tm5 tumor cell line
provides the possibility to study the role of the B1 receptor in
tumor progression without the interference of B2 receptor
signaling.
Activation of the kinin B1 receptor in the absence of B2
receptor impairs melanoma cells migration in vitro
To address the functional role of the B1 receptor in cellular
events related to tumor progression, we first evaluated the effect of
its agonist DABK in modulating cell migration. According to the in
vitro wound healing assay shown in figure 2A–B, incubation with
DABK for 24 h leads to ,50% reduction in wound closure with
partial recovery when pre-incubated with the antagonist. Evalu-
ation of the single cell migration profile from the same assay also
yielded ,50% reduction in the group treated with DABK
(figure 2C). To rule out the possibility that the observed
impairment in migration could be due to a possible cytostatic/
cytotoxic effect, we evaluated cell viability up to 48 h in the
presence of the aforementioned ligands. As shown in figure 2D,
neither incubation with DABK nor with DLBK changed the
number of viable cells. In addition, we also observed that the
inhibitory effects of B1 receptor activation in cell migration is likely
to be related to E-cadherin because activation of the B1 receptor
resulted in increased expression of this adhesion molecule
(p = 0.0642) (figure 2E). To evaluate a possible cell line specific
effect of DABK over Tm5 cell migration, we also evaluated
B16F10 cells. Accordingly, B16F10 murine melanoma cells were
screened for kinin receptors profile and, as shown in figure S1A,
these cells do express B1 receptor and do not have detectable levels
of B2 receptor mRNA. Moreover, similarly to Tm5 cells, B16F10
cells showed impaired migration in the presence of DABK
(figure S1B–C) as well as reduced single cell migration in the
wound healing assay (figure S1D). Interestingly, such inhibitory
effect of B1 receptor on cell migration is dependent on the absence
of B2 receptor, as expression of B2 receptor in Tm5 cells
completely rescued their full migration profile after stimulation
with DABK (figure 2F–H).
Activation of the B1 receptor in pre-implanted tumor
cells decreases tumor formation and peritumor
inflammatory infiltrate in vivo
To evaluate the role of the B1 receptor in tumor progression in
vivo, we stimulated Tm5 melanoma cells in vitro with DABK, the
B1 receptor agonist, prior to implantation in mice [16]. While
approximately 80% of the animals that received non-treated
control cells developed tumors up to 28 days after implantation,
only approximately 40% of animals that received DABK-treated
melanoma cells developed tumors (figure 3A). In other words,
more than 60% of the animals from the DABK-treated group
remained tumor-free during this period. Indeed, we monitored
tumor size daily from non-stimulated and DABK-stimulated Tm5
melanoma cells engrafted in mice and as seen in figure 3B the
growth curves of the control and DABK-tumors are quite
different. Although tumors in both groups appear at a similar
time-point, DABK-tumors are markedly smaller than control
tumors. Likewise, at day 28 after cell implantation, the average
tumor mass in the control group was 1.2 g, while in DABK-
treated group, the average tumor mass was 0.2 g (figure 3C). The
histopathological analysis of the tumors from both groups revealed
significant changes in the stroma of the control group but minor
changes in the DABK-stimulated tumors (figure 3D, dashed line).
Because previous studies have shown that a high number of
infiltrated inflammatory cells correlates with a poor prognosis in
melanoma [41], we decided to assess whether tumors from
DABK-stimulated cells had a lower number of infiltrated immune
cells. As shown in figure 3E, there are significantly fewer
macrophages, neutrophils and lymphocytes in the area surround-
ing the tumor in the DABK-stimulated tumors. Nonetheless, even
with fewer immune cells, the tumor that originated from the
DABK-stimulated cells had higher levels of IL-6 and IFN-c
mRNA (figure 3F), which are pro-inflammatory cytokines known
to be important in the anti-tumor immune response [42].
Melanomas generated from DABK-treated cells show
decreased proliferation and vascularization in vivo
We next performed comparative histopathological analyses with
tumor samples from the two groups (control and DABK-treated
cells). Tumors generated from DABK-treated cells had signifi-
cantly less mitotic cells and a poorer vascular network compared to
tumors from the control group (figure 4A). Histological findings
were further confirmed by immunostaining for proliferation and
endothelial markers. In figure 4B, we show representative images
and quantification of Ki67 staining in control and tumors
generated from DABK-treated cells. The DABK-treated tumors
show significant lower levels of Ki67 positive cells as compared to
tumors from the control group. A similar scenario is seen in
figure 4C, where we show that CD31 staining is also decreased in
tumors originated from DABK-treated cells as compared to non-
stimulated cells. The ability of tumor cells to grow and metastasize
is related to their capacity to undergo morphological/functional
changes that will enable those cells to become more motile. In this
sense, we assessed expression levels of the adhesion molecule E-
cadherin within the tumor mass as well as of TGF-b, a cytokine
known for regulating key steps on motility of epithelial cells by
inducing EMT. As shown in figure 4D–E, tumors originated from
DABK-stimulated cells have higher E-cadherin mRNA levels and
lower TGF-b mRNA levels, which correlates with impaired
migration capability observed in vitro (see figure 2). These results
suggest that in addition to impairing primary tumor growth, B1
receptor activation could also play a role in inhibiting metastasis.
Activation of the B1 receptor in melanoma cells
decreases metastasis and increases animal survival
To address whether B1 receptor activation plays an inhibitory
role in tumor progression and metastasis, we performed
histopathological analyses that revealed extremely aggressive
features in tumors generated from Tm5 melanoma cells. These
cells do not show a well-established capsule and frequently invade
surrounding tissues, as shown in figure 5A. Moreover, we also
observed spontaneous lymph node metastases in 75% (9/12) of the
control mice (figure 5B, inner panel and 5A). Conversely, tumors
from DABK-treated cells presented a clear capsule delimitating
tumor borders, and we did not observe any invasion into the
surrounding tissues, as shown in figure 5A, or any lymph node
metastases (0/12) in animals implanted with DABK-treated tumor
cells (figure 5B).
To evaluate the possibility of late and recurrent onset of disease,
we monitored survival up to 150 days after control or DABK-
stimulated cell implantation. Strikingly, we observed that animals
that did not developed a tumor within the first 30 days after
implantation with DABK-stimulated cells were still alive and
tumor-free after 5 months, while 100% of animals that received
control cells had to be euthanized as late as the beginning of the
second month (figure 5C).
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Discussion
The kallikrein-kinin system has a pivotal role in inflammation
and vascular permeability systemically. However, many new
pathophysiological functions have been attributed to this system
since it has been discovered that most of the components of the
system can have a local role in different organs, including brain
[43–45]. The kallikrein-kinin system role in cancer is far from
being completely understood, even though the prostate-specific
antigen (PSA), which is currently a key marker for prostate cancer
diagnostics [46], is in fact a kallikrein. Indeed, several other
kallikreins have been described as potential biomarkers for tumor
progression [47–48]. While recent studies started to uncover the
underlying mechanisms by which the kallikrein-kinin system
modulates tumor progression, mainly concerning to the B2
receptor, many aspects remain to be elucidated. In this study,
we report that the kinin B1 receptor in the presence of its agonist
(DABK) and in the absence of the B2 receptor plays a host
protective role during murine tumor progression.
The presence of the kinin B2 and B1 receptors in neoplastic
tissues has been reported in various tumor cell lines and in patient
biopsies [21,23,49]. Indeed, it has been shown that blocking the
B2 receptor with specific antagonists decreases tumor size,
angiogenesis and metastasis [22,50–51] and that the B1 receptor
also seems to play a pro-tumor role in prostate cancer [23]. Most
of the studies relating the kallikrein-kinin system to cancer were
performed in models expressing both the B1 and B2 receptors
[23,25,29]. It is important to mention that a critical role for the
cross talk between the B1 and B2 receptors in kinin-mediated
proliferation in androgen-insensitive prostate tumor cells has been
reported [30]. Thus, we believe that the reported pro-tumor role
for the B1-receptor is most likely due to the cross talking effect with
the B2 receptor. Here, we demonstrate that the Tm5 murine
melanoma cell line constitutively and uniquely expresses a
functional B1 receptor, while the B2 receptor is not present. We
took advantage of this finding to address the particular contribu-
tion of the B1 receptor in tumor progression.
After Tm5 cells stimulation with the B1 receptor agonist DABK
we observed increased intracellular calcium concentration and
Figure 2. Activation of the kinin B1 receptor in the absence of kinin B2 receptor inhibits melanoma cell migration in vitro. Wound
healing assays were performed to evaluate the role of the B1 receptor in melanoma cell migration, (A) representative image and quantification of
healing (B) and single cell migration (C) of 4 independent experiments in triplicate. (D) Cell viability was accessed using the MTT assay 24 and 48 h
after DABK or DLBK stimulation; (E) E-cadherin mRNA expression levels were evaluated by RT-qPCR 24 h after B1 receptor agonist stimulation.
Introduction of kinin B2 receptor in B2 receptor-free cells abrogates DABK-mediated migration inhibition (F–H). (All results are from 2–3 independent
experiments performed in triplicate, unless otherwise stated). DABK: desArg9-bradykinin; DLBK: desArg9-[Leu8]-bradykinin. Data are expressed as the
mean 6 SEM; * p,0.05; ** p,0.01; *** p,0.001; **** p,0.0001. The scale bars represent 200 mm.
doi:10.1371/journal.pone.0064453.g002
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also increased levels of ERK phosphorylation, but no alteration in
cell proliferation. Previous reports using systems in which both
receptors are expressed, describe an induction of cell proliferation,
which suggests that the B2 receptor may be required for pro-
proliferative effects of DABK. Actually, we observed that in vivo
tumors exposed to DABK presented several elements of decreased
aggressiveness, including less proliferating Ki67 positive cells
within the tumor mass. While the mechanisms underlying such in
vivo inhibitory effects remains to be elucidated, the interface
tumor/host seems to play a major role. One possibility is the
Figure 3. Stimulation of melanoma cells with the B1 receptor agonist reduces tumor growth and peritumor inflammatory
infiltration after in vivo implantation. (A) Incidence of animals with palpable tumor 28 days after injection of DABK stimulated cells. (B) Tumor
growth curve from control and DABK-stimulated cells injected in C57/Bl6 mice. (C) Average tumor weight 28 days after tumor cell injection (D)
Representative images at low magnification showing the size of the peritumor inflammatory infiltrate (upper panel, dashed line and arrow) and at
high magnification showing the immune cells present in the tumor stroma (lower panel, * macrophage, arrow – neutrophil, dashed arrow –
lymphocyte). (E) Peritumor inflammatory infiltrate assessed by quantification of the number of macrophages, neutrophils and lymphocytes in ten
different high magnification fields (A = 400x; n = 6). (F) Detection of TNF-a, IL-6 and IFN-c cytokine expression in the tumor mass as assessed by RT-
qPCR (n = 6). In vivo studies of primary tumor growth n= 12; Data are expressed as the mean 6 SEM; * p,0.05; ** p,0.01; *** p,0.001; DABK:
desArg9-bradykinin; DLBK: desArg9-[Leu8]-bradykinin. Scale bars represent 200 mm and 50 mm in the upper and lower panels, respectively.
doi:10.1371/journal.pone.0064453.g003
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immune system act as a key player by decreasing in vivo tumor
proliferation, as we have observed changes in the cytokine profile
within the tumor mass when comparing control and DABK-
treated tumors. Furthermore, a significant decrease in melanoma
cell migration was observed in vitro. The ability of the B1 receptor
to disrupt cell migration has been previously described in non-
neoplastic arterial smooth muscle cells [31], although this effect
has not previously been reported in tumor cells. The mechanisms
underlying the inhibition of cell migration are not yet clear.
However, as previously reported [40] an increase in the expression
of adhesion molecules, such as E-cadherin, can strongly decrease
cell migration. Moreover, corroborating with previous data
reporting a functional role for B1/B2 receptors cross talk [30],
we show that introduction of B2 receptor in Tm5 cells completely
abrogated the B1-mediated effect of decreasing cell migration,
reinforcing a pivotal role for the B1/B2 receptors cross talk in
cellular response and ultimately in tumor progression.
Our model also allowed us to specifically address whether the
B1 receptor could play a role in tumor progression in vivo. In this
sense, Tm5 cells were stimulated in vitro with DABK and 24 h later
implanted into mice. This approach allowed us to evaluate the
contribution of the B1 receptor without the interference of a cross
talk with the B2 receptor. This aspect is especially important
considering that the agonists of both receptors differ only by the
presence or absence of a C-terminal arginine residue [10].
Remarkably, our data show that implantation of B1 receptor-
stimulated cells resulted in a decreased the incidence of tumor
formation. Besides that, tumors generated from B1 receptor-
stimulated cells exhibited a significant decrease of inflammatory
cells infiltration. This result is particularly interesting because in
many solid tumors, the presence of a high number of inflammatory
cells within the tumor area correlates with a poor prognosis [52].
Moreover, corroborating with a decreased incidence of tumor
formation, we found that within the tumor mass, which includes
tumor and host cells, mRNA levels of two pro-inflammatory
cytokines, IL-6 and IFN-c, were up-regulated in tumors from B1
receptor-stimulated cells compared to controls. Although inflam-
mation has been shown to be a hallmark of cancer [53], and
several pro-inflammatory cytokines play a role in tumor progres-
sion [54], IFN-c and IL-6 have been described as key elements in
host anti-tumor immune response [42]. It may be possible that
activation of the B1 receptor, by inducing secretion of cytokines
and chemokines, could attract and activate immune cells within
the tumor area. In this sense, lymphocytes would be able to
Figure 4. Stimulation of melanoma cells with the B1 receptor agonist decreases tumor proliferation and vascularization after in vivo
implantation. (A) Histological analysis of tumors generated from non-stimulated or DABK-stimulated melanoma cells (Rmitotic cells, blood
vessels). Number of mitotic cells and blood vessels were evaluated from ten different high magnification fields (A = 10640, n = 6). Scale bars represent
50 mm. (B) Immunohistochemistry analysis of proliferation marker Ki-67. Scale bars represent 50 mm (C) Immunohistochemistry analysis of blood
vessel marker CD-31. Scale bars represent 200 mm. E-cadherin (D) and TGF-b (E) mRNA expression within the tumor mass was evaluated by RT-qPCR
(n = 6). Data are expressed as the mean 6 SEM; * p,0.05; ** p,0.01; *** p,0.001; **** p,0.0001; DABK: desArg9-bradykinin.
doi:10.1371/journal.pone.0064453.g004
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successfully elicit an anti-tumor immune response, which then
could explain the higher levels of IFN-c observed in the tumor
mass of tumors from DABK-treated cells [42]. On the other hand,
lymphocytes recruited to tumors from the control group showed to
be associated with lower levels of IFN-c. This allow us to speculate
that tumor cells possibly were able to evade immune response by
inducing anergy and/or senescence of T cells [55], or even
inducing differentiation of T cells into T regulatory cells, which
would then lead to a down regulation of immune response. In fact
this hypothesis seems fairly coherent with the increased levels of
TGF-b observed in control tumors when compared with tumors
originated from DABK-treated cells, as it is known that tumor cells
as well as regulatory T cells secrete TGF-b to inhibit immune
response [56].
Tumors originated from DABK-stimulated cells also displayed
patterns of decreased aggressiveness, such as fewer proliferating
cells and a poorer vascular network. Another feature of
aggressiveness is the ability of tumor cells to detach from the
primary tumor and reach the circulation to colonize secondary
organs and metastasize [2]. One of the required steps for a tumor
cell to metastasize is to acquire a more motile and less adhesive
phenotype. Therefore, we hypothesized that tumors originated
from DABK-stimulated cells would also display reduced metastasis
ability. In this sense, we observed that DABK-stimulated tumors
had significantly higher levels of the adhesion molecule E-
cadherin. Placing these findings in context, they suggest that
activation of the B1 receptor by its agonist reprogrammed
melanoma cells, which then generated less aggressive primary
tumors, less prone to metastasize, and that ultimately improved
animal survival.
Several studies have shown that ACE (as also known as kininase
II) inhibition resulted in anti-tumor effects. [12–13]. Indeed, ACE
is a key functional point connecting the renin-angiotensin system
and the kallikrein-kinin system, being responsible for AngII
formation as well as for kinin degradation [19–20]. Therefore,
any inhibition/impairment in ACE functionality ultimately leads
to a decrease in AngII levels and to an increase in kinin
availability. In this context, it seems discordant that ACE blockade
could play its anti-tumor role by increasing the activity of a pro-
tumor system, i.e., the kallikrein-kinin system. Hence, it is
tempting to speculate that the anti-tumor properties of ACE
inhibitors might not be exclusively mediated by impairment of the
renin-angiotensin system axis, but in fact may also involve the
kallikrein-kinin system axis.
Taken together, our results show that activation of the GPCR
kinin B1 receptor plays a host protective role during Tm5
melanoma progression in mice. The B1 receptor stimulation
decreases melanoma cell migration and decreases tumor growth,
proliferation, vascularization and immune cell infiltration, while
increasing the expression of the pro-inflammatory and anti-tumor
cytokines IFN-c and IL-6. All these factors contributed to the
complete absence of lymph node metastases and improved animal
survival. The identification of a new GPCR with anti-tumor
properties opens new avenues for the development and discovery
of new potential pharmacological targets to treat tumor growth
and dissemination, such the use of selective non-peptide B1
receptor agonists. These findings also have major implications for
Figure 5. Activation of the B1 receptor in melanoma cells decreases metastasis and increases animal survival. (A) Representative
images of the tumor borders showing the invasive behavior of tumors derived from non-stimulated cells and the well-delimited borders of tumors
derived from DABK-stimulated cells. The inner panel in the control picture shows a representative image of a metastatic lymph node (* tumor cells
invading muscle tissue;R well delimited and encapsulated tumor border). (B) Number of animals with lymph node metastases (C) Survival curve of
C57/Bl6 mice that received control or DABK-stimulated tumor cells. n = 12 for lymph nodes metastasis analysis and n= 5 for survival study; Data are
expressed as the mean 6 SEM; * p,0.05; DABK: desArg9-bradykinin.
doi:10.1371/journal.pone.0064453.g005
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ACE inhibitors, which are widely used to treat hypertension, and
their effects on a concomitant tumor disease, which require further
investigation.
Supporting Information
Figure S1 Activation of the kinin B1 receptor inhibits
cell migration of B16F10 melanoma cells in vitro. (A)
B16F10 melanoma cells express B1 receptor, but do not express
kinin B2 receptor. B1 receptor activation decreases collective (B–
C) and single cell migration (B and D) in B16F10 melanoma cell
line. DABK: desArg9-bradykinin; n = 3 independent experiments
performed in triplicate; Data are expressed as the mean 6 SEM;
**** p,0.0001. The scale bars represent 200 mm.
(TIF)
Table S1 Primers sequences, temperature of melting
and fragment size obtained in semi-quantitative PCR
(sqPCR) and/or quantitative PCR (qPCR). Bp: base pairs;
Tm: temperature of melting; CPM: carboxypeptidase M; TGF-b:
transforming growth factor beta; INF-c: interferon-gamma.
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